🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 13/05/2008 | 27,70 | 27,70 | 26,61 | 26,92 | -2,82% | 3,94% | 1.821.300 |
| 12/05/2008 | 27,01 | 27,80 | 26,99 | 27,70 | +2,97% | 3,00% | 1.353.700 |
| 09/05/2008 | 26,26 | 27,18 | 26,00 | 26,90 | +1,39% | 4,49% | 1.911.000 |
| 08/05/2008 | 25,70 | 26,91 | 25,70 | 26,53 | +4,04% | 4,71% | 1.726.700 |
| 07/05/2008 | 26,33 | 26,50 | 25,22 | 25,50 | -3,37% | 4,86% | 1.353.300 |
| 06/05/2008 | 26,20 | 26,64 | 25,91 | 26,39 | +0,42% | 2,79% | 1.284.600 |
| 05/05/2008 | 26,35 | 26,46 | 25,72 | 26,28 | -0,04% | 2,81% | 988.000 |
| 02/05/2008 | 26,62 | 26,90 | 25,93 | 26,29 | -0,79% | 3,64% | 1.051.900 |
| 01/05/2008 | 25,71 | 26,62 | 25,47 | 26,50 | +3,84% | 4,47% | 1.364.400 |
| 30/04/2008 | 26,37 | 26,66 | 25,28 | 25,52 | -3,30% | 5,23% | 1.886.100 |
| 29/04/2008 | 25,91 | 26,64 | 25,80 | 26,39 | +2,41% | 3,24% | 2.330.100 |
| 28/04/2008 | 26,00 | 26,20 | 24,89 | 25,77 | +0,19% | 5,04% | 3.078.400 |
| 25/04/2008 | 24,85 | 25,73 | 24,49 | 25,72 | +3,29% | 4,99% | 2.523.400 |
| 24/04/2008 | 24,90 | 25,34 | 23,75 | 24,90 | -4,05% | 6,39% | 4.737.600 |
| 23/04/2008 | 27,30 | 27,44 | 25,09 | 25,95 | -3,89% | 8,61% | 3.973.900 |
| 22/04/2008 | 26,65 | 28,66 | 26,54 | 27,00 | +2,54% | 7,95% | 4.155.300 |
| 21/04/2008 | 25,70 | 26,73 | 25,49 | 26,33 | +2,21% | 4,82% | 1.779.100 |
| 18/04/2008 | 25,95 | 26,38 | 25,30 | 25,76 | +1,14% | 4,16% | 2.237.300 |
| 17/04/2008 | 26,00 | 26,69 | 25,47 | 25,47 | -2,30% | 4,69% | 1.650.700 |
| 16/04/2008 | 25,87 | 26,42 | 25,75 | 26,07 | +0,66% | 2,59% | 1.828.100 |
| 15/04/2008 | 25,89 | 26,13 | 24,88 | 25,90 | +0,00% | 4,83% | 2.438.500 |
| 14/04/2008 | 25,65 | 26,03 | 25,15 | 25,90 | +0,97% | 3,43% | 1.810.500 |
| 11/04/2008 | 26,20 | 26,29 | 25,38 | 25,65 | -2,43% | 3,47% | 1.411.300 |
| 10/04/2008 | 26,56 | 27,24 | 26,15 | 26,29 | -0,76% | 4,10% | 3.381.200 |
| 09/04/2008 | 26,34 | 26,51 | 25,36 | 26,49 | +1,53% | 4,37% | 2.691.700 |
| 08/04/2008 | 25,85 | 26,29 | 25,60 | 26,09 | +0,73% | 2,67% | 1.608.000 |
| 07/04/2008 | 26,24 | 26,43 | 25,77 | 25,90 | -1,48% | 2,52% | 1.514.200 |
| 04/04/2008 | 25,54 | 26,55 | 25,44 | 26,29 | +3,50% | 4,35% | 3.335.800 |
| 03/04/2008 | 24,92 | 25,92 | 24,59 | 25,40 | +2,38% | 5,34% | 2.867.900 |
| 02/04/2008 | 25,31 | 25,52 | 24,59 | 24,81 | -2,36% | 3,67% | 4.340.300 |